Figure 10: Wt1 lineage tracing in mice and expression in human tumours.
From: The Wilms’ tumour suppressor Wt1 is a major regulator of tumour angiogenesis and progression
(a) FACS-based quantification of Wt1-dependent (GFP-expressing) cells in organs of Wt1CreERT2;mTmG mice after tamoxifen induction with or without tumour cell injection. Note the higher percentage of GFP+ cells in bone marrow (BM), spleen and blood in tumour-bearing animals (n=3 each). (b) FACS results for B16 and LLC1 tumours (n=3 each). Wt1-dependent cells in the tumour are GFP+; non-Wt1-dependent cells from the host are Tomato positive. (c) Representative FACS example from a LLC1 tumour. (d) FACS analysis of contribution of endothelial cells, haematopoietic progenitor cells (HPCs) and myeloid-derived suppressor cells (MDSCs) to the tumour and (e) determination of the percentage of Wt1-dependent cells in each of these cell types (n=3 for B16, n=3 for LLC1). (f) Double-labelling of WT1 with Pecam-1 (endothelial cells), CD34 (endothelial, haematopoietic cells), WT1/CD45 (haematopoietic cells, MDSCs), WT1/CD33 (MDSCs) and WT1/desmin (pericytes) in human tumour samples. Scale bars, 50 μm. Data are the mean±s.e.m. *P<0.05, **P<0.01, ***P<0.001.
